Desktop Site
|
24 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Watch List
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,852.94
+114.49
+0.16 %
Corporate Announcement
Security Code
530019
Company
Jubilant Pharmova Ltd
Exchange Received Time
21/03/2017 08:45:31
Exchange Disseminated Time
21/03/2017 08:45:32
Time Taken
00:00:01
Updates |
3/21/2017 8:45:31 AM
Sub: Disclosure under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Jubilant Pharma Limited ('JPL'), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a specialty pharma business in the United States using only internal accruals, , subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.
Attachment
<< Back
Recently Viewed